[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2743266T3 - Inhibitory kinazy białkowej (warianty), ich zastosowanie w leczeniu chorób onkologicznych i oparta na nich kompozycja farmaceutyczna - Google Patents

Inhibitory kinazy białkowej (warianty), ich zastosowanie w leczeniu chorób onkologicznych i oparta na nich kompozycja farmaceutyczna

Info

Publication number
PL2743266T3
PL2743266T3 PL12801171T PL12801171T PL2743266T3 PL 2743266 T3 PL2743266 T3 PL 2743266T3 PL 12801171 T PL12801171 T PL 12801171T PL 12801171 T PL12801171 T PL 12801171T PL 2743266 T3 PL2743266 T3 PL 2743266T3
Authority
PL
Poland
Prior art keywords
variants
pharmaceutical composition
protein kinase
kinase inhibitors
composition based
Prior art date
Application number
PL12801171T
Other languages
English (en)
Inventor
Germes Grigorievich Chilov
Ilya Yurievich Titov
Original Assignee
Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma" filed Critical Obshchestvo S Ogranichennoy Otvetstvennostyou "Fusion Pharma"
Publication of PL2743266T3 publication Critical patent/PL2743266T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12801171T 2011-06-16 2012-05-29 Inhibitory kinazy białkowej (warianty), ich zastosowanie w leczeniu chorób onkologicznych i oparta na nich kompozycja farmaceutyczna PL2743266T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011124304/04A RU2477723C2 (ru) 2011-06-16 2011-06-16 Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе

Publications (1)

Publication Number Publication Date
PL2743266T3 true PL2743266T3 (pl) 2017-02-28

Family

ID=47357651

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12801171T PL2743266T3 (pl) 2011-06-16 2012-05-29 Inhibitory kinazy białkowej (warianty), ich zastosowanie w leczeniu chorób onkologicznych i oparta na nich kompozycja farmaceutyczna

Country Status (22)

Country Link
US (1) US9522910B2 (pl)
EP (1) EP2743266B8 (pl)
AU (1) AU2012269818B2 (pl)
CA (1) CA2850137C (pl)
CY (1) CY1118513T1 (pl)
DK (1) DK2743266T3 (pl)
EA (1) EA026704B1 (pl)
ES (1) ES2602797T3 (pl)
HK (1) HK1195771A1 (pl)
HR (1) HRP20161478T1 (pl)
HU (1) HUE031837T2 (pl)
IL (1) IL232357A (pl)
IN (1) IN2014MN00635A (pl)
LT (1) LT2743266T (pl)
PL (1) PL2743266T3 (pl)
PT (1) PT2743266T (pl)
RS (1) RS55380B1 (pl)
RU (1) RU2477723C2 (pl)
SI (1) SI2743266T1 (pl)
SM (1) SMT201600398B (pl)
UA (1) UA115228C2 (pl)
WO (1) WO2012173521A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3521291A1 (en) 2010-05-20 2019-08-07 Array Biopharma, Inc. Macrocyclic compounds as trk kinase inhibitors
CN103420977B (zh) * 2012-05-16 2016-06-22 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) * 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
CN103664787B (zh) * 2012-09-17 2015-09-09 南京圣和药业股份有限公司 炔杂芳环化合物及其应用
CN104341416B (zh) * 2013-07-31 2017-03-29 南京圣和药业股份有限公司 蛋白酪氨酸激酶抑制剂及其应用
KR20160127076A (ko) * 2014-03-06 2016-11-02 유니버시티 오브 써던 캘리포니아 전통적인 화학 요법-약물 효능 및 유용성을 강화시키고 정상 세포와 조직에서 키나제의 부작용을 반전시키기 위한 키나제 억제제와 조합된 단기 기아 요법의 사용
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN106146391A (zh) * 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
RU2652992C2 (ru) * 2016-04-18 2018-05-04 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Новая кристаллическая солевая форма 3-(1,2,4-триазоло[4,3-а]пиридин-3-илэтинил)-4-метил-n-(4-((4-метилпиперазин-1-ил)метил)-3-трифторметилфенил)бензамида для медицинского применения
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
RU2664420C1 (ru) * 2017-10-31 2018-08-17 Общество С Ограниченной Ответственностью "Фьюжн Фарма" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ДОЗИРОВКА И СПОСОБ ЛЕЧЕНИЯ Ph+ ЛЕЙКЕМИЙ
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
AU2019372057A1 (en) * 2018-11-02 2021-05-27 Merck Sharp & Dohme Llc 2-amino-N-heteroaryl-nicotinamides as NAV1.8 inhibitors
KR20220009349A (ko) * 2020-07-14 2022-01-24 보로노이바이오 주식회사 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 예방 또는 치료용 약학적 조성물
GB202209210D0 (en) * 2022-06-23 2022-08-10 Univ Strathclyde Cycloaddition reactions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290944A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
AU2005206571B8 (en) 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EP1896395B1 (en) 2005-06-24 2015-07-15 Merck Sharp & Dohme Corp. Modified malonate derivatives
US8114874B2 (en) * 2005-12-23 2012-02-14 Ariad Pharmaceuticals, Inc. Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
EP1989203A2 (en) 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha carbolines and uses thereof
CA2651822A1 (en) * 2006-05-08 2007-11-22 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
CA2655362A1 (en) 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7612085B2 (en) 2006-07-11 2009-11-03 Washington University Sigma 2 receptor ligands and therapeutic uses therefor
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2008156783A2 (en) 2007-06-18 2008-12-24 University Of Louisville Research Foundation, Inc. Family of pfkfb3 inhibitors with anti-neoplastic activities
EP2235002B1 (en) 2008-01-23 2012-11-21 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
US8188109B2 (en) 2009-07-20 2012-05-29 Naxospharma S.R.L. Benzoquinolizinium salt derivatives as anticancer agents
US8242282B2 (en) 2010-05-18 2012-08-14 Taipei Medical University Histone deacetylase inhibitors
RU2011113236A (ru) 2011-04-07 2012-10-20 Общество с ограниченной ответственностью "Фьюжн Фарма" (RU) Новые химические соединения для лечения онкологических заболеваний
CN103420977B (zh) * 2012-05-16 2016-06-22 上海医药集团股份有限公司 具有抗肿瘤活性的乙炔衍生物
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors

Also Published As

Publication number Publication date
EP2743266B8 (en) 2016-09-28
AU2012269818A1 (en) 2014-06-26
ES2602797T3 (es) 2017-02-22
SMT201600398B (it) 2017-01-10
IL232357A (en) 2017-05-29
RS55380B1 (sr) 2017-03-31
HUE031837T2 (en) 2017-08-28
EP2743266A4 (en) 2015-03-11
AU2012269818B2 (en) 2016-05-19
EA026704B1 (ru) 2017-05-31
US9522910B2 (en) 2016-12-20
PT2743266T (pt) 2016-10-14
HRP20161478T1 (hr) 2016-12-16
UA115228C2 (uk) 2017-10-10
CA2850137C (en) 2016-10-25
CA2850137A1 (en) 2012-12-20
IL232357A0 (en) 2014-07-01
IN2014MN00635A (pl) 2015-07-03
WO2012173521A3 (ru) 2013-03-28
RU2477723C2 (ru) 2013-03-20
HK1195771A1 (zh) 2014-11-21
CY1118513T1 (el) 2017-07-12
WO2012173521A2 (ru) 2012-12-20
RU2011124304A (ru) 2012-12-27
DK2743266T3 (en) 2016-12-05
EP2743266B1 (en) 2016-08-17
SI2743266T1 (en) 2017-02-28
LT2743266T (lt) 2016-12-12
EP2743266A2 (en) 2014-06-18
US20140213592A1 (en) 2014-07-31
EA201491356A1 (ru) 2015-01-30

Similar Documents

Publication Publication Date Title
HK1195771A1 (zh) 蛋白質激酶抑制劑 變體 ，其在治療腫瘤學疾病中的用途以及基於此的藥物組合物
EP2743269A4 (en) PIM KINASE INHIBITOR, PREPARATION METHOD AND USE IN PREPARING THE MEDICINAL PRODUCT
HK1246674A1 (zh) 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法
HK1200451A1 (zh) 蛋白激酶抑制劑
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
IL231271A0 (en) Inhibitors of monooxygenase - 3 - kynurenine, pharmaceutical compositions, and methods of their use
EP2694517A4 (en) PROTEIN KINASE INHIBITORS
LT2729151T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
EP2683243A4 (en) PI3 KINASE INHIBITORS AND USES THEREOF
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
IL230705A0 (en) Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
ZA201306855B (en) Protein kinase inhibitors
IL230504A0 (en) Selective protein kinase inhibitors
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
GB201106095D0 (en) N-Substituted mannosamine derivatives, process for their preparation and use thereof
EP2762148A4 (en) NEW PHOSPHATIDYLINOSITOL-3-KINASEINHIBITOR AND PHARMACEUTICAL COMPOSITION